Skip to main content

Pfizer-BioNTech COVID-19 Booster Update

Last updated on 1/12/2022

On January 3, 2022, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to include:

  • Authorization of a booster dose for people 12 and older.
  • A shortened interval of 5 months between a booster dose and completion of the primary vaccine series for people 12 and older.
  • A third primary series dose allowed for certain immunocompromised children 5 to 11 years old.

The Texas Health and Human Services Commission (HHSC) allows pharmacy benefit coverage of the Pfizer-BioNTech COVID-19 vaccine in compliance with the expanded use authorized by the FDA.

Email with questions or comments.